We are live on ! Find out more
BBH icon

VanEck Biotech ETF

115 hedge funds and large institutions have $152M invested in VanEck Biotech ETF in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more capital inflows, than outflows

Capital inflows: $11.8M | Capital outflows: $8.08M

1.02% more ownership

Funds ownership: 32.93% → 33.94% (+1%)

1% less funds holding

Funds holding: 116 → 115 (-1)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

28% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 29

Holders
115
Holders Change
-1
Holders Change %
-0.86%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
21
Reduced
29
Closed
9
Calls
$2.22​M
Puts
–
Net Calls
+$2.22​M
Net Calls Change
+$1.26​M

BBH Hedge Fund Activity: Q3 2024 in Review

115 of the 6,990 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2024, worth a combined $152M — up 7% from $142M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of BBH and 8 opened new positions — a net loss of 1 holder — while 29 trimmed existing stakes and 21 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $3.87M. The largest seller was Susquehanna International Group, cutting an estimated $1.55M.

  • 115 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2024, down from 116 in Q2 2024.
  • Funds reported $152M of VanEck Biotech ETF stock for Q3 2024, up 7% quarter-over-quarter.
  • 8 funds opened new VanEck Biotech ETF positions in Q3 2024 and 9 closed out, a net change of -1 holder.
  • The largest VanEck Biotech ETF buyer in Q3 2024 was Citadel Advisors, an estimated $3.87M added.
  • The largest VanEck Biotech ETF seller in Q3 2024 was Susquehanna International Group, an estimated $1.55M sold.

Based on aggregated 13F filings for Q3 2024.